NCT05000229 (Post-Covid) is a clinical trial in Post-Covid Syndrome, sponsored by Lithuanian University of Health Sciences.

Who is sponsoring NCT05000229?

NCT05000229 is sponsored by Lithuanian University of Health Sciences.

What condition does NCT05000229 study?

NCT05000229 studies Post-Covid Syndrome.

Is NCT05000229 still recruiting?

NCT05000229 is currently status unknown. Last updated 11 August 2021.

Last reviewed 2021-08-11 · How we verify

NCT05000229: Post-Covid

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Residual Symptoms After Coronavirus Disease (COVID-19) in Lithuanian Population

Status unknown Last updated 11 August 2021

What this trial tests

trial in Post-Covid Syndrome in 5,000 participants. Status unknown.

Timeline

4 May 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Lithuanian University of Health Sciences
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	5,000
Start date	4 May 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Lithuania

Conditions studied

Post-Covid Syndrome — all drugs for Post-Covid Syndrome →

Sponsor

Lithuanian University of Health Sciences

Who can join

18 and older, any sex, with Post-Covid Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to describe the post-covid-19 syndrome in Lithuanian population regarding the remaining symptoms and their impact on physical functioning, work ability and needs of rehabilitation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Do Comorbidities and Daily Medication before SARS-CoV-2 Infection Play a Role in Self-Reported Post-Infection Symptoms?
Važgėlienė D, Kubilius R, Bileviciute-Ljungar I. · · 2022 · cited 3× · PMID 36362506 · DOI 10.3390/jcm11216278
The Impact of Previous Comorbidities on New Comorbidities and Medications after a Mild SARS-CoV-2 Infection in a Lithuanian Cohort.
Važgėlienė D, Kubilius R, Bileviciute-Ljungar I. · · 2024 · PMID 38276129 · DOI 10.3390/jcm13020623

Verify or expand the search:

Other Lithuanian University of Health Sciences trials

Trials by the same sponsor.

NCT07477873 — Evaluation of Emotional Responses Using the I-Motions System and Self-assessment Questionnaires, and Assessment of Posto · NA · enrolling by invitation
NCT07476976 — Characteristics of the Functional State of the Musculoskeletal System, Body Awareness, and Quality of Life in Individual · enrolling by invitation
NCT07284446 — Depressive Symptoms, Cognitive Impairment, and Outcomes in Hospitalized Chronic Heart Failure Patients · recruiting
NCT07097675 — The Change in Psychoemotional State of Individuals With Dementia Syndrome Applying Art Therapy · NA · not yet recruiting
NCT06800222 — Effectiveness of Modern Physical Agents in the Treatment of Pelvic Floor Dysfunctions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05000229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lithuanian University of Health Sciences
Last refreshed: 11 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05000229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing